A. David Arkowitz's most recent trade in iBio Inc was a trade of 13,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on Nov. 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| iBio Inc | David A. Arkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2025 | 13,500 | 13,500 | - | - | Stock Option (right to buy) | |
| Kineta Inc | David A. Arkowitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 30 Jun 2025 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kineta Inc | A. David Arkowitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 30 Jun 2025 | 16,571 | 0 | - | - | Common Stock | |
| Kineta Inc | David Arkowitz A. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 30 Jun 2025 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Kineta Inc | David A. Arkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2025 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Kineta Inc | David A. Arkowitz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 23 Jun 2025 | 12,500 | 16,847 | - | 0.6 | 7,638 | Common Stock |
| Kineta Inc | David A. Arkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2025 | 6,000 | 18,141 | - | 0 | Common Stock | |
| Kineta Inc | David A. Arkowitz | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.26 per share. | 23 Jun 2025 | 4,706 | 12,141 | - | 0.3 | 1,224 | Common Stock |
| iBio Inc | David A. Arkowitz | Director | Purchase of securities on an exchange or from another person at price $ 2.72 per share. | 10 Jan 2025 | 18,382 | 18,382 (0%) | 0% | 2.7 | 49,999 | Common Stock |
| Kineta Inc | David A. Arkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | A. Arkowitz David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 287,905 | 287,905 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Arkowitz David A. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 213,750 | 213,750 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 35,625 | 35,625 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | David Arkowitz A. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 10,625 | 31,875 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | David Arkowitz A. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 10,625 | 186,381 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Arkowitz A. David | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.08 per share. | 14 Feb 2024 | 3,939 | 182,442 (0%) | 0% | 1.1 | 4,254 | Common Stock |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 42,500 | 166,613 (0%) | 0% | 0 | Common stock | |
| Kineta Inc | David A. Arkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Kineta Inc | David A. Arkowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 42,500 | 42,500 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 3.15 per share. | 05 Jul 2022 | 63,492 | 65,492 (0%) | 0% | 3.2 | 200,000 | COMMON STOCK |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 42,500 | 112,992 (0%) | 0% | 0 | Common stock | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 5,000 | 0 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | David A. Arkowitz | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 5,000 | 70,492 (0%) | 0% | 0 | Common stock | |
| Seres Therapeutics Inc | David A. Arkowitz | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) |